Professor of Oncology and Medicine, Director Leukemia Program, Johns Hopkins
Oncology
Dr. Judith E. Karp, MD
|
|
Give Review
Judith Karp practices Oncology. She attended Stanford University School of Medicine. Stanford University School of Medicine is a one of the best medicals schools. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine Judith Karp is a published doctor and has 19 publications published. The lastest was: '4EBP1/c-MYC/PUMA and NFB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.'
Publications
- Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.
- 4EBP1/c-MYC/PUMA and NFκB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
- Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
- Precision medicine for acute myeloid leukemia.
- Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
- New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.
- BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
- A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
- Epidemiology of Candida kefyr in Patients with Hematologic Malignancies.
- Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant, and after relapse post-transplant.
- The state of the union on treatment of acute myeloid leukemia.
- Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.
- Personalized therapy for acute myeloid leukemia.
- Minimal residual disease in acute myeloid leukaemia.
- CD30 in myeloid malignancies: hitting the bull's-eye with an available dart.
- Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy.
- Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib...
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
Schools
Stanford University
Stanford Hospital
Johns Hopkins Hospital
Doctors Specialties
- Internal Medicine
- Oncology
Accepted Insurances
Education
-
Johns Hopkins University -
Stanford University -
Stanford University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Kenneth M. Zonies, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christian B. Gocke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aderonke O. Falayi, MD |
|
|
Dr. Walid K. Barbour, MD |
|
|
Dr. Helen Gharwan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christie A. Brillante, MD |
|
|
Dr. Kalpana Atluri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen H. Glasser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mei Tang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew T. Whitehurst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diana E. Amariei, MD |
|
|
Dr. Ambachew G. Woreta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ephraim J. Fuchs, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ashraf Z. Badros, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|